Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature
Findings in epigenetic changes in meylodysplastic syndromes (MDS) and the development of demethylating drugs provide a new approach to the treatment of MDS. We used standard-dose decitabine for treatment of MDS in an elderly patient with an International Prostate Symptom Score (IPSS) of moderate risk group 2, and achieved a complete response in the first course. We report our experience with this case and review the relevant literatures.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Nan fang yi ke da xue xue bao = Journal of Southern Medical University - 32(2012), 2 vom: 30. Feb., Seite 280-2 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Gao, Ya [VerfasserIn] |
|---|
| Themen: |
776B62CQ27 |
|---|
| Anmerkungen: |
Date Completed 26.09.2013 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM215864549 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM215864549 | ||
| 003 | DE-627 | ||
| 005 | 20231224030426.0 | ||
| 007 | tu | ||
| 008 | 231224s2012 xx ||||| 00| ||chi c | ||
| 028 | 5 | 2 | |a pubmed24n0719.xml |
| 035 | |a (DE-627)NLM215864549 | ||
| 035 | |a (NLM)22381778 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Gao, Ya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 26.09.2013 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Findings in epigenetic changes in meylodysplastic syndromes (MDS) and the development of demethylating drugs provide a new approach to the treatment of MDS. We used standard-dose decitabine for treatment of MDS in an elderly patient with an International Prostate Symptom Score (IPSS) of moderate risk group 2, and achieved a complete response in the first course. We report our experience with this case and review the relevant literatures | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Decitabine |2 NLM | |
| 650 | 7 | |a 776B62CQ27 |2 NLM | |
| 650 | 7 | |a DNA Modification Methylases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a Azacitidine |2 NLM | |
| 650 | 7 | |a M801H13NRU |2 NLM | |
| 700 | 1 | |a Ping, Baohong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Shuyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nan fang yi ke da xue xue bao = Journal of Southern Medical University |d 2006 |g 32(2012), 2 vom: 30. Feb., Seite 280-2 |w (DE-627)NLM16087646X |x 1673-4254 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2012 |g number:2 |g day:30 |g month:02 |g pages:280-2 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2012 |e 2 |b 30 |c 02 |h 280-2 | ||